Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07116629 · ClinicalTrials.gov registry record
Catch A Vibe - 24-00864
A clinical trial, sponsored by NYU Langone Health.
- Recruiting
- Registry status
- 343
- Enrollment target
NCT07116629: Recruiting study, sponsored by NYU Langone Health.
NCT07116629 is a clinical trial that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 343 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07116629 is actively recruiting participants, sponsored by NYU Langone Health.
- RECRUITING
- Registry status
- 343 participants
- Enrollment target
Study Summary
This study evaluates a proposed community-based implementation strategy to scale up screening, identification, and intervention on Health-Related Social Needs (HRSN) among persons on Long-Acting Injectable Pre-exposure Prophylaxis (LAI-PrEP). To do so, (1) screening for HRSN will occur at provider visits every 4 months, (2) navigation and establishment of connections with community resources through collaboration with two established community-based organization (CBO) partners, and (3) development of a tracking system integrated into the Electronic Medical Record (EMR) for monitoring and assessment of referral outcomes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 343 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2028-05 |
What NCT07116629 shows while recruiting
NCT07116629 is an observational study that tracks outcomes without assigning an intervention. The registered 343 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07116629 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07116629 about?
NCT07116629 is a clinical study titled "Catch A Vibe - 24-00864". This study evaluates a proposed community-based implementation strategy to scale up screening, identification, and intervention on Health-Related Social Needs (HRSN) among persons on Long-Acting Injectable Pre-exposure Prophylaxis (LAI-PrEP). To do so, (1) screening for HRSN will occur at provider v...
What is the current status of trial NCT07116629?
This trial is currently recruiting. The enrollment target is 343 participants. The study started on 2025-10-22. Estimated completion is 2028-05.
Who is sponsoring clinical trial NCT07116629?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06733363 · 344 participants · Phase 2
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
- NCT07179380 · 344 participants · Phase 3
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- NCT07304024 · 344 participants · Phase 1
A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound
- NCT05283850 · 342 participants · Phase 2
Surviving PEA in Roanoke (SPEAR) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI